Brief: Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
22/11/2024 11:38
Nov 22 (Reuters) - Akeso Inc 9926.HK :
* AKESO'S PENPULIMAB COMBINATION THERAPY FOR FIRST-LINE
TREATMENT
OF HEPATOCELLULAR CARCINOMA ACCEPTED BY NMPA
Source text: ID:nPn8T46TNa
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals